Ki67: A time-varying biomarker of risk of breast cancer in atypical hyperplasia

Breast Cancer Research and Treatment

Volumn 121, Issue 2, 2010, Pages 431-437

  Santisteban, Marta ^a   Reynolds, Carol ^b   Barr Fritcher, Emily G ^b   Frost, Marlene H ^b   Vierkant, Robert A ^b   Anderson, Stephanie S ^b   Degnim, Amy C ^b   Visscher, Daniel W ^c   Pankratz, V Shane ^b   Hartmann, Lynn C ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Atypical hyperplasia; Breast cancer risk; Immunohistochemistry; Ki 67

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST HYPERPLASIA; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DISEASE MARKER; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INCIDENCE; KI-67 ANTIGEN; MIDDLE AGED; PRECANCEROUS CONDITIONS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953022837     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0534-7     Document Type: Article

References (39)

1. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW (2007) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3): 229-237
2. Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, Pankratz VS, de Groen. PC, Lingle WL, Ghosh K, Penheiter L, Tlsty T, Melton U 3rd, Reynolds CA, Hartmann LC (2007) Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 25(19): 2671-2677
3. London SJ, Connolly JL, Schnitt SJ, Colditz GA (1992) A prospective study of benign breast disease and the risk of breast cancer. JAMA 267(7): 941-944
4. Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312(3): 146-151
5. Chlebowski RT (2000) Reducing the risk of breast cancer. N Engl J Med 343(3): 191-198
6. Pankratz VS, Hartmann LC, Degnim AC, Vierkant RA, Ghosh K, Vachon CM, Frost MH, Maloney SD, Reynolds C, Boughey JC (2008) Assessment of the accuracy of the gail model in women with atypical hyperplasia. J Clin Oncol 26(33): 5374-5379
7. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1): 57-70
8. Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31(1): 13-20
9. Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8(1): 47-61
10. Rudas M, Neumayer R, Gnant MF, Mittelbock M, Jakesz R, Reiner A (1997) p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer 33(1): 39-44 (Pubitemid 27099565)
11. Shoker BS, Jarvis C, Davies MP, Iqbal M, Sibson DR, Sloane JP (2001) Immunodetectable cyclin D(1) is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br J Cancer 84(8): 1064-1069
12. Imamura H, Haga S, Shimizu T, Watanabe O, Kajiwara T, Aiba M (1999) Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma. Br J Cancer 79(1): 172-178
13. Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16(11): 1723-1739
14. Balleine RL, Webster LR, Davis S, Salisbury EL, Palazzo JP, Schwartz GF, Cornfield DB, Walker RL, Byth K, Clarke CL, Meltzer PS (2008) Molecular grading of ductal carcinoma in situ of the breast. Clin Cancer Res 14(24): 8244-8252
15. Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, Maloney SD, Pankratz VS, Degnim AC, Vachon CM, Reynolds CA, Thompson RA, Melton LJ 3rd, Goode EL, Visscher DW (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98(22): 1600-1607
16. Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55(11): 2698-2708
17. Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6): 695-706
18. Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimaki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC (2008) Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 100(6): 421-427
19. Liu S, Edgerton SM, Moore DH 2nd, Thor AD (2001) Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res 7(6): 1716-1723
20. Natarajan L, Pu M, Parker BA, Thomson CA, Caan BJ, Flatt SW, Madlensky L, Hajek RA, Al-Delaimy WK, Saquib N, Gold EB, Pierce JP (2009) Time-varying effects of prognostic factors associated with disease-free survival in breast cancer, Am J Epidemiol 169(12): 1463-1470
21. Lundin J, Lehtimaki T, Lundin M, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Isola J, Joensuu H (2006) Generalisability of survival estimates for patients with breast cancer-a comparison across two population-based series. Eur J Cancer 42(18): 3228-3235
22. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78(1): 105-118
23. Adami HO, Graffman S, Lindgren A, Sallstrom J (1985) Prognostic implication of estrogen receptor content in breast cancer. Breast Cancer Res Treat 5(3): 293-300
24. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG (1983) Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43(6): 2985-2990
25. Santen RJ, Mansel R (2005) Benign, breast disorders. N Engl. J Med 353(3): 275-285
26. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28): 7212-7220
27. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM (2006) Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24(19): 3019-3025
28. Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orland L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M (2008) Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 99(10): 1564-1571
29. Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14(24): 8019-8026
30. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-I study. J Natl Cancer Inst 90(18): 1371-1388
31. Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med; 348(7): 618-629
32. Dunn BK, Wickerham DL, Ford LG (2005) Prevention of hormone-related cancers: breast cancer. J Clin. Oncol 23(2): 357-367
33. Shaaban AM, Sloane JP, West CR, Foster CS (2002) Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptoralpha and Ki-67 expression, Am J Pathol 160(2): 597-604
34. Hameed O, Ghali VS, Tartter PI, Mizrachi H (2005) Immunohistochemical staining for cyclin D1 and Ki-67 aids in the stratification of atypical ductal hyperplasia diagnosed on breast core biopsy. Am J Clin Pathol 124(6): 862-872
35. Cazzaniga M., Severi G, Casadio C, Chiapparini L, Veronesi. U, Decensi A (2006) Atypia and Ki-67 expression from ductal lavage in women at different risk for breast cancer. Cancer Epidemiol Biomarkers Prev 15(7): 1311-1315
36. Khan QJ, Kimler BF, Clark J, Metheny T, Zalles CM, Fabian CJ (2005) Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration. Cancer Epidemiol Biomarkers Prev 14(4): 786-789
37. Bloom K, Harrington D (2004) Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol 121(5): 620-630
38. Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ (2006) Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology 48(3): 258-267
39. Zhang K, Prichard JW, Yoder S, De J, Lin F (2007) Utility of SKP2 and MIB-1 in grading follicular lymphoma using quantitative imaging analysis. Hum Pathol 38(6): 878-882